A total of 170 of 1318 patients in the younger group (12.90%) were categorized as having the HR–/ERBB2+ subtype; 8 of these patients (4.71%), with median follow-up of 128 months (IQR, 87-163 months), developed CBC. This evidence concerns the gene ERBB2 and complete blood cell count.